SpringWorks Therapeutics (SWTX) Announces $225 Million Private Placement Financing

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to SpringWorks Therapeutics (SWTX) Announces $225 Million Private Placement Financing

SpringWorks Therapeutics Inc. (SWTX) to Resume Trading at 10:25 a.m.

September 7, 2022 10:04 AM EDT

SpringWorks Therapeutics Inc. (NASDAQ: SWTX) to Resume Trading at 10:25 a.m.

... More

SpringWorks Therapeutics (SWTX) Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma

September 7, 2022 9:55 AM EDT

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it has entered into an expanded global, non-exclusive license and collaboration agreement with GSK plc (LSE/NYSE: GSK) for nirogacestat, SpringWorks investigational oral gamma secretase inhibitor, in combination with Blenrep (belantamab mafodotin-blmf), GSKs antibody-drug conjugate targeting B-cell maturation antigen (BCMA).

Under the terms of the expanded agreement, SpringWorks will receive a $75 million equity investment from GSK, with shares of common... More